Filtered By:
Condition: Heart Attack
Drug: Celebrex

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 23 results found since Jan 2013.

FDA strengthens warning that NSAIDs increase heart attack and stroke risk
Back in 2005, the FDA warned that taking nonsteroidal anti-inflammatory drugs (NSAIDs) like ibuprofen and naproxen increased the risk of having a heart attack or stroke. Last week it took the unusual step of further strengthening this warning. This was done on the advice of an expert panel that reviewed new information about NSAIDs and their risks. Because NSAIDs are widely used, it’s important to be aware of downsides of taking an NSAID and to take steps to limit the risk. Many people take NSAIDs to relieve mild to moderate pain. These medications may be particularly effective in conditions in which pain results pri...
Source: New Harvard Health Information - July 13, 2015 Category: Consumer Health News Authors: Gregory Curfman, MD Tags: Heart Health heart attack heart disease NSAIDS Stroke Source Type: news

Cardiovascular risk associated with celecoxib or etoricoxib: a meta-analysis of randomized controlled trials which adopted comparison with placebo or naproxen.
CONCLUSION: On the basis of our meta-analysis, we can state that symptomatic benefits induced by the prolonged administration of celecoxib may be partially invalidated by a concomitant increase in vascular risk, particularly the increased risk of myocardial infarction found in celecoxib-treated patients, compared to controls taking placebo. In contrast, treatment with etoricoxib proved not to result in an increased risk of serious vascular events when compared with both the placebo and naproxen. Our meta-analysis also denotes that the alternative to COXIBs, represented by naproxen, does not show significant benefit in term...
Source: Minerva Cardioangiologica - November 18, 2015 Category: Cardiology Tags: Minerva Cardioangiol Source Type: research

How To Avoid China ’ s Medicine Monopoly
I want to share a shocking statistic with you… Around 80% of all the pharmaceuticals sold in America — both prescription and over-the-counter — are manufactured in China. I’m talking about drugs for Parkinson’s and Alzheimer’s, blood pressure and blood thinners, diuretics, aspirin, antibiotics, and a big chunk of the world’s insulin and diabetes drugs — just to name a few.1 We don’t even make penicillin anymore. The last penicillin plant in the U.S. closed its doors in 2004. Americans who rely on medicine are now almost entirely at the mercy of a country whose relations with the U.S. have become more ...
Source: Al Sears, MD Natural Remedies - September 19, 2023 Category: Complementary Medicine Authors: Jacob Tags: Health Source Type: news

High-dose painkiller heart risk: small but significant
Conclusion This large review adds to, and expands on, the current evidence on the risks of vascular disease and gastrointestinal complications for different NSAIDs. It largely concentrates on trials of high doses of NSAIDs that can only be prescribed by a doctor. It is unclear from this study whether there is any risk from taking lower doses available over the counter. While most experts advise that low-dose NSAIDs, taken occasionally, are safe for most people, an accompanying editorial points out that there are still “large gaps” in evidence on the risks with lower doses of NSAIDs. While the risk to individuals is sma...
Source: NHS News Feed - May 30, 2013 Category: Consumer Health News Tags: Medication Heart/lungs Source Type: news

Non ‐steroidal anti‐inflammatory drug‐induced cardiovascular adverse events: a meta‐analysis
Summary What is known and objectiveAlthough non‐steroidal anti‐inflammatory drugs (NSAIDs) have been studied in randomized, controlled trials and meta‐analyses in an effort to determine their cardiovascular (CV) risks, no consensus has been reached. These studies continue to raise questions, including whether cyclooxygenase‐2 (COX‐2) selectivity plays a role in conferring CV risk. We performed a meta‐analysis of current literature to determine whether COX‐2 selectivity leads to an increased CV risk. MethodsWe utilized randomized, controlled trials and prospective cohort studies. We selected eight NSAIDs based...
Source: Journal of Clinical Pharmacy and Therapeutics - November 30, 2016 Category: Drugs & Pharmacology Authors: B. R. Gunter, K. A. Butler, R. L. Wallace, S. M. Smith, S. Harirforoosh Tags: Review Article Source Type: research

Godly gift for arthritis pain
Big Pharma is at it again… Creating and selling a drug that causes thousands of heart attacks and strokes each year. In 2015, the FDA asked drug makers to strengthen their warning labels. Since then, most have listed their dangerous side effects on the bottle. But one manufacturer thought they didn’t have to warn people about their dangerous drug. They marketed their product as a “unique” breakthrough. They even published studies promising it was “safe for long-term use.” 1 The drug is a 7-year-old arthritis drug called Actemra. It’s made by the Swiss pharmaceutical company Roche. ...
Source: Al Sears, MD Natural Remedies - October 5, 2017 Category: Complementary Medicine Authors: Al Sears Tags: Anti-Aging Source Type: news

Comparative evaluation of cardiovascular outcomes in patients with osteoarthritis and rheumatoid arthritis on recommended doses of nonsteroidal anti-inflammatory drugs
Conclusion: From the analysis conducted, it appears that the risk for cardiovascular events in arthritis patients on licensed doses of NSAIDs varies considerably and is likely to depend on the individual compound.
Source: Therapeutic Advances in Musculoskeletal Disease - August 4, 2014 Category: Orthopaedics Authors: Fabule, J., Adebajo, A. Tags: Original Research Source Type: research

Some Pain Drugs Increase the Risk of Heart Attack
ROCHESTER, Minn. — Some of the most common pain drugs used by older adults who experience discomfort in muscles and joints can increase the risk of heart attack and stroke. The April issue of Mayo Clinic Health Letter covers the risks of nonsteroidal anti-inflammatory drugs (NSAIDs) that include celecoxib (Celebrex), diclofenac (Voltaren), ibuprofen (Advil, Motrin [...]
Source: Mayo Clinic Health Information - April 26, 2013 Category: Consumer Health News Source Type: news

Nonsteroidal Anti-Inflammatory Drugs and Cardiovascular Outcomes in Women: Results From the Women's Health Initiative Original Articles
Conclusions— Regular use of selective cox-2 inhibitors and nonselective NSAIDs with cox-2>cox-1 inhibition showed a modestly increased hazard for cardiovascular events. Nonselective agents with cox-1>cox-2 inhibition were not associated with increased cardiovascular risk. Clinical Trial Registration— URL: www.clinicaltrials.gov. Unique identifier: NCT00000611.
Source: Circulation: Cardiovascular Quality and Outcomes - July 15, 2014 Category: Cardiology Authors: Bavry, A. A., Thomas, F., Allison, M., Johnson, K. C., Howard, B. V., Hlatky, M., Manson, J. E., Limacher, M. C. Tags: Risk Factors Original Articles Source Type: research

FDA Strengthens Warnings on Class of Painkillers
The FDA strengthened its safety warnings about heart-attack and stroke risks linked to a class of common pain relievers that includes medicines such as Celebrex, Advil, Motrin IB and Aleve.
Source: WSJ.com: Health - July 10, 2015 Category: Pharmaceuticals Tags: PAID Source Type: news

Celebrex Is No Riskier For Heart Than Other Arthritis Drugs, Study Finds
NEW ORLEANS (AP) — A new study gives some reassurance to arthritis sufferers who want pain relief but are worried about side effects. It finds that Celebrex, a drug similar to ones withdrawn 12 years ago for safety reasons, is no riskier for the heart than some other prescription pain pills that are much tougher on the stomach. “We do not want patients to suffer with pain and we need to know what is safe to give them,” said Dr. Steven Nissen, the Cleveland Clinic’s heart chief, who led the study. Fear that Celebrex would be worse than alternatives proved unfounded, and “on almost every endpoint it...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - November 14, 2016 Category: Consumer Health News Authors: Health – CBS Boston Tags: Health News Arthritis Celebrex Source Type: news

Celebrex study shows less risk to heart health than expected
Researchers spend a decade studying Celebrex, an arthritis drug, to see if it causes heart problems. A similar drug was removed from the market in 2004, as it increased the risk of heart attack and stroke. Dr. Jon LaPook reports.
Source: Health News: CBSNews.com - November 15, 2016 Category: Consumer Health News Source Type: news

Celecoxib ’s Cardiovascular Safety
The selective cyclooxygenase 2 (COX-2) inhibitor celecoxib is no more likely than 2 nonsteroidal anti-inflammatory drugs (NSAIDs) to cause cardiovascular death, nonfatal myocardial infarction, or stroke in patients with coronary disease or other cardiovascular risks.
Source: JAMA - December 27, 2016 Category: Journals (General) Source Type: research

Nonsteroidal anti-inflammatory drugs and cardiovascular safety - translating pharmacological data into clinical readouts.
Authors: Tacconelli S, Bruno A, Grande R, Ballerini P, Patrignani P Abstract INTRODUCTION: The pharmacological management of pain includes the use of nonsteroidal anti-inflammatory drugs(NSAIDs). They comprise traditional(t) NSAIDs and selective cyclooxygenase(COX)-2 inhibitors (named coxibs). The analgesic and anti-inflammatory effects of NSAIDs are dependent on the extent and duration of COX-2 inhibition in the spinal cord and inflammatory sites. However, the simultaneous inhibition of COX-2 in the vasculature translates into a prothrombotic phenotype and promotes hypertension and heart failure. Areas covered. Th...
Source: Expert Opinion on Drug Safety - June 2, 2017 Category: Drugs & Pharmacology Tags: Expert Opin Drug Saf Source Type: research

Celecoxib for rheumatoid arthritis.
CONCLUSIONS: Celecoxib may improve clinical symptoms, alleviate pain and contribute to little or no difference in physical function compared with placebo. Celecoxib was associated with fewer numbers of participant withdrawals. Results for incidence of gastroduodenal ulcers (≥ 3 mm) and short-term serious adverse events were uncertain; however, there were few reported events for either.Celecoxib may slightly improve clinical symptoms compared with tNSAIDs. Results for reduced pain and improved physical function were uncertain. Particpants taking celecoxib had lower incidence of gastroduodenal ulcers (≥ 3 mm) and there w...
Source: Cochrane Database of Systematic Reviews - June 9, 2017 Category: General Medicine Authors: Fidahic M, Jelicic Kadic A, Radic M, Puljak L Tags: Cochrane Database Syst Rev Source Type: research